CJC-1295
Also known as: CJC-1295 DAC, Modified GRF 1-29
Growth hormone-releasing hormone analog
Mechanism of Action
Stimulates growth hormone release from the pituitary. Often combined with a GHRP for synergistic effects.
Reported Outcomes
Clinical Strength: DBased on community reports (78 posts). Grade reflects frequency and consistency of positive mentions.
Changes in muscle vs fat ratio
Effects on sleep quality
Reduction in body weight
Changes in energy and fatigue levels
Effects on mood and cognitive function
Reduced hunger and food cravings
Improved glycemic control and insulin sensitivity
Side Effects
Based on 40 user reports. Frequency indicates how often each was mentioned.
Common (>5%)
Uncommon (1-5%)
Dosing
Standard Protocol
- Starting Dose
- 100mcg 1-3x daily (no DAC) or 2mg weekly (with DAC)
- Titration
- No established protocol
- Half-life
- ~30 min (no DAC) or ~8 days (with DAC)
- Administration
- Subcutaneous injection
Community Dosing Patterns
Based on 47 mentions
Community-reported patterns, not medical advice.
Pricing
Research-grade reference pricing for 5mg vial. Prices vary by vendor and quantity.
We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.
US Research Grade
Single small vial from US domestic vendors
US Research Grade (Bulk)
Per-dose equivalent when buying larger US vials
China Research Grade
Per-vial when buying 10-pack from Chinese vendors
74% savings
Research
Key Studies
Anal Sci Adv (2022)
Anal Bioanal Chem (2016)
Commonly Stacked With
Based on 78 community posts mentioning CJC-1295.
Switching Patterns
Based on 6 discussions about switching to or from CJC-1295.